Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Fibrodysplasia Ossificans Progressiva (FOP) Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for BMP-4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BMP-4 Mature Protein / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View BMP4 Products |
| Gene Delivery | BMP-4 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View BMP4 Products |
| Benchmark Ab | Anti-BMP-4 Benchmark Antibody Recombinant positive control. Sequence Verified. |
View BMP4 Products |
| Validator | BMP-4 siRNA Set For knockdown verification. |
View BMP4 Products |
| Related Target A | BMPR1A (ALK3) Primary Type I receptor mediating BMP-4 signaling. |
View BMPR1A Products |
| Related Target B | BMP-2 Highly homologous target required for strict selectivity and off-target counter-screening. |
View BMP-2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| High Homology within TGF-β Superfamily (Off-target binding) | Homolog panel proteins (e.g., BMP-2, BMP-7) available with >95% purity and strictly verified by mass spec. |
| Native Dimeric Folding & Disulfide Knot Formation | Mammalian expression (HEK293) ensures Native Glycosylation and theoretical MW conformity for precise structural mimicry. |
| Lack of Reliable Controls | Clinical Benchmark Antibodies included for comparative SPR/BLI binding assays. |
| False Positives in Phenotypic Screening | Sequence-verified siRNA included for precise specificity checks in target-knockdown cell lines. |
Live BMP-4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for BMP-4 therapeutics is intensifying, as the target's dual role in both driving osteogenesis and promoting tumor metastasis becomes clearer. Historically utilized as a recombinant biologic for bone regeneration, modern discovery pipelines are shifting focus toward BMP-4 neutralizing monoclonal antibodies and traps for oncology (e.g., hepatocellular carcinoma, breast cancer) and rare genetic bone disorders like Fibrodysplasia Ossificans Progressiva (FOP). As first-generation systemic therapies face safety hurdles regarding bone density and cardiovascular effects, the next wave of R&D is targeting highly localized delivery systems, conditional activation, and bispecific antibodies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Neutralizing mAbs | Multiple biopharmas | Oncology (Metastasis) | Selectivity Assay (Need High-Purity Homologs to avoid BMP-2 cross-reaction) |
| Recombinant Traps | Acceleron / Merck | Pulmonary Arterial Hypertension | Affinity Validation (Need correctly folded, native-dimer BMP-4 antigen) |
| Small Molecules | Blueprint Medicines (ALK2 inhibitors) | FOP | Cell-based Reporter Assays (Need pure BMP-4 to induce specific downstream Smad signaling) |